Legal & General Group
AVTX icon

Legal & General Group’s Avalo Therapeutics AVTX Stock Holding History

Legal & General Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$74.9K Buy
+4,055
New +$64.1K ﹤0.01% 2675
2022
Q3 		– Sell
-1
Closed -$2K – 3456
2022
Q2 		$2K Sell
1
-1
-50% -$1.34K ﹤0.01% 3486
2022
Q1 		$4K Hold
2
– – ﹤0.01% 3516
2021
Q4 		$9K Hold
2
– – ﹤0.01% 3473
2021
Q3 		$12K Hold
2
– – ﹤0.01% 3408
2021
Q2 		$18K Buy
2
+1
+100% +$8.38K ﹤0.01% 3321
2021
Q1 		$13K Sell
1
-1
-50% -$9.45K ﹤0.01% 3293
2020
Q4 		$13K Hold
2
– – ﹤0.01% 3235
2020
Q3 		$11K Hold
2
– – ﹤0.01% 3188
2020
Q2 		$12K Buy
2
+1
+100% +$7.26K ﹤0.01% 3256
2020
Q1 		$8K Sell
1
-1
-50% -$10.6K ﹤0.01% 3195
2019
Q4 		$24K Buy
2
+1
+100% +$10.5K ﹤0.01% 3127
2019
Q3 		$12K Hold
1
– – ﹤0.01% 3239
2019
Q2 		$18K Buy
+1
New +$15.2K ﹤0.01% 3233

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Legal & General Group's AVTX Position: Q2 2026 in Review

Legal & General Group opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 4,055 shares worth $74.9K. The stake represents ﹤0.01% of the portfolio and ranks #2675 among its holdings. This is a return to the name: Legal & General Group previously reported a position in AVTX as recently as Q2 2022.

Legal & General Group first reported a position in AVTX in Q2 2019 and has held it in 14 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Legal & General Group held 4,055 shares of Avalo Therapeutics worth $74.9K as of Q2 2026.
  • Avalo Therapeutics was a new Legal & General Group position in Q2 2026.
  • Avalo Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2675 holding.
  • Legal & General Group first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 14 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.